Summary
Edwards Lifesciences Corporation reported strong performance in its 2024 fiscal year, with net sales reaching $5.4 billion, an increase of 8.6% year-over-year. This growth was primarily driven by robust sales in its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments. The company also made significant strategic moves, including the sale of its Critical Care product group for $4.2 billion and several key acquisitions aimed at strengthening its position in structural heart disease and expanding into heart failure management. Key financial highlights include a notable increase in net income and diluted earnings per share, supported by top-line growth and the positive impact of the Critical Care divestiture. The company's commitment to innovation is evident in its continued investment in research and development, representing 19% of net sales in 2024, with advancements in its TAVR and TMTT platforms. Edwards Lifesciences remains focused on its patient-centric strategy, aiming to transform care for those with structural heart disease and expanding its reach in interventional heart failure technologies.
Financial Highlights
52 data points| Revenue | $5.44B |
| Cost of Revenue | $1.12B |
| Gross Profit | $4.32B |
| R&D Expenses | $1.05B |
| SG&A Expenses | $1.79B |
| Operating Income | $1.38B |
| Net Income | $4.17B |
| EPS (Basic) | $6.98 |
| EPS (Diluted) | $6.97 |
| Shares Outstanding (Basic) | 597.70M |
| Shares Outstanding (Diluted) | 599.30M |
Key Highlights
- 1Net sales increased by 8.6% to $5.4 billion, driven by TAVR and TMTT product growth.
- 2Successfully completed the sale of its Critical Care product group for $4.2 billion, refocusing the company on structural heart and heart failure.
- 3Acquired Endotronix, Inc., Innovalve Bio Medical Ltd., and JC Medical, Inc. to bolster its portfolio in heart failure management and transcatheter mitral replacement/regurgitation.
- 4Research and Development (R&D) investment increased by 9% year-over-year, representing 19% of net sales, underscoring commitment to innovation.
- 5Received FDA approval and launched the EVOQUE tricuspid valve replacement system in the U.S.
- 6Announced positive results from key clinical trials such as EARLY TAVR and TRISCEND II, supporting the adoption of early intervention and new therapies.
- 7Repurchased $1.2 billion of common stock in 2024, demonstrating a commitment to shareholder returns.